Document Detail


Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma.
MedLine Citation:
PMID:  21319292     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Circulating endothelial cells (CECs) have been detected at increased numbers in patients with solid cancers. CECs have not been systematically evaluated in patients with osteosarcoma.
PROCEDURE: Patients 12 months to 30 years of age with newly diagnosed high-grade osteosarcoma were eligible for this prospective cohort study. Patients provided a single blood sample at study entry for CEC quantification by flow cytometry at a single reference laboratory. CECs were defined as CD146+, CD31+, CD45-, and CD133-. CEC progenitor cells (CEPs) were defined as CD146+, CD31+, CD45-, and CD133+.
RESULTS: Eighteen patients enrolled (11 males; median age 16 years; range 5-21 years). CEC counts did not differ between patients with osteosarcoma compared to seven pediatric healthy controls (median 645 cells/ml, range 60-5,320 cells/ml vs. 1,670 cells/ml, range 330-4,700 cells/ml, respectively; P = 0.12). CEP counts did not differ between patients compared to controls (median 126 cells/ml, range 0-5,320 cells/ml vs. median 260 cells/ml, range 0-10,670 cells/ml, respectively; P = 0.69). CEC and CEP counts did not correlate with metastatic status, tumor size, or histologic response to neoadjuvant chemotherapy.
CONCLUSIONS: CEC and CEP levels are not increased in patients with osteosarcoma compared to healthy controls. CECs and CEPs do not correlate with clinical features of osteosarcoma. Alternative novel markers of disease burden and response are needed in this disease.
Authors:
Steven G DuBois; Diana Stempak; Bing Wu; Reza Bayat Mokhtari; Rakesh Nayar; Katherine A Janeway; Robert Goldsby; Holcombe E Grier; Sylvain Baruchel
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-02-11
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  58     ISSN:  1545-5017     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2011-12-14     Completed Date:  2012-01-31     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  181-4     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Wiley Periodicals, Inc.
Affiliation:
Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA. duboiss@peds.ucsf.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antigens, CD / blood
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Neoplasms / blood,  drug therapy,  pathology*
Case-Control Studies
Child
Child, Preschool
Cohort Studies
Endothelial Cells / metabolism,  pathology*
Female
Flow Cytometry
Follow-Up Studies
Humans
Male
Neoadjuvant Therapy
Neoplasm Metastasis
Neoplastic Cells, Circulating / metabolism,  pathology*
Osteosarcoma / blood,  drug therapy,  pathology*
Prognosis
Prospective Studies
Stem Cells / metabolism,  pathology*
Tumor Markers, Biological / blood*
Young Adult
Grant Support
ID/Acronym/Agency:
KL2 RR024130/RR/NCRR NIH HHS; KL2 RR024130/RR/NCRR NIH HHS; KL2 RR024130-05/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antigens, CD; 0/Tumor Markers, Biological
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.
Next Document:  Nanostructured titanium promotes keratinocyte density.